Oren Gilad - Mar 27, 2025 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
President/CEO, Director
Signature
/s/ John P. Hamill, as Attorney-in-Fact
Stock symbol
APRE
Transactions as of
Mar 27, 2025
Transactions value $
$0
Form type
4
Date filed
3/31/2025, 04:30 PM
Previous filing
Oct 24, 2024
Next filing
Apr 4, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Award $0 +6.73K +2.02% $0.00 340K Mar 27, 2025 Direct F1
holding APRE Common Stock 1.2K Mar 27, 2025 By Daughter F2
holding APRE Common Stock 600 Mar 27, 2025 By Son F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Stock Options (Right to Buy) Award $0 +26.9K $0.00 26.9K Mar 27, 2025 Common Stock 26.9K $2.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 27, 2026, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F3 Twenty-five percent of these options vest on March 27, 2026, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.